Sen. Grassley Considers Proposing Legislation That Would Require Not-for-Profit Hospitals To Spend A Minimum Amount On Charity Care, More

January 16, 2009

Senate Finance Committee ranking member Chuck Grassley (R-Iowa) might propose legislation in the first quarter of 2009 that would attempt to hold not-for-profit hospitals accountable for the billions of dollars in tax exemptions they receive annually, according to members of Grassley’s staff, the Wall Street Journal reports. Grassley is working on the legislation with other Senate members, including Sen. Jeff Bingaman (D-N.M.). The aides noted that Grassley first plans to urge the Treasury Department to reinstate charity care requirements that the Internal Revenue Service eliminated in 1969 before proposing new legislation.
Read the rest of this entry »

Advertisements

Grassley Inquiry Into Fast-Tracking Of Drug Applications Could Hurt Cancer Drug Development, Patients, Op-Ed States

December 25, 2008

Sen. Chuck Grassley’s (R-Iowa) request that the Government Accountability Office investigate whether FDA acted appropriately in granting “accelerated approval” to a cancer drug “will have a catastrophic effect on America’s ability to develop new drugs,” Mark Thornton, a former medical officer in FDA’s Office of Oncology Drug Products and president of the Sarcoma Foundation of America, writes in a Wall Street Journal opinion piece. The drug, Avastin, was granted accelerated approval for treating women with metastatic breast cancer after showing early evidence of an effect on the “surrogate endpoint” known as “progression-free survival,” according to Thornton.
Read the rest of this entry »


Grassley Inquiry Into Fast-Tracking Of Drug Applications Could Hurt Cancer Drug Development, Patients, Op-Ed States

May 30, 2008

Sen. Chuck Grassley’s (R-Iowa) request that the Government Accountability Office investigate whether FDA acted appropriately in granting “accelerated approval” to a cancer drug “will have a catastrophic effect on America’s ability to develop new drugs,” Mark Thornton, a former medical officer in FDA’s Office of Oncology Drug Products and president of the Sarcoma Foundation of America, writes in a Wall Street Journal opinion piece. The drug, Avastin, was granted accelerated approval for treating women with metastatic breast cancer after showing early evidence of an effect on the “surrogate endpoint” known as “progression-free survival,” according to Thornton.
Read the rest of this entry »